The global cell-free DNA (cfDNA) testing market is anticipated to register a CAGR of 18.52% between the forecasted years of 2018-2026
The global cell-free DNA (cfDNA) testing market is
anticipated to register a CAGR of 18.52% between the forecasted years of
2018-2026. Factors such as the global increase in the number of people
suffering from chronic diseases, advances in molecular pathogenesis and a surge in prenatal complication are increasing
the market demand for cell-free DNA testing.
To know more about the latest trends, analysis of the global cell-free DNA (cfDNA) market, request a free sample copy
MARKET
INSIGHTS
The Global Cell-free DNA (cfDNA)
testing market is segmented on the basis of products, platforms and
applications. The product segment of this market includes automated
instruments, consumables and extraction/isolation kits. The extraction
isolation kits can be either magnetic bead-based,
column-based or other
extraction/isolation kits. The various platforms for the cell-free DNA testing
market are NGS, rPCR and multiplexed PCR,
qPCR, dPCR and other platform. The market
chiefly finds its application in areas
like oncology, NIPT and other disease conditions.
REGIONAL
INSIGHTS
Regional segmentation of the
global cell-free DNA market is done into Asia-Pacific, Europe, North America,
and rest of the world. The North American market is likely to account for the
highest revenue share by the end of the forecast period of 2018-2026. The
growing prevalence of cancer is increasing the demand for cell-free DNA tests.
These tests are also being employed in prenatal screening.
COMPETITIVE
INSIGHTS
The leading companies
operating in this market are Agilent
Technologies Inc, Accubiomed, Aline
Biosciences, Berry Genomics, Bioo Scientific Corporation, F. Hoffmann-La Roche Ltd, Gatc Biotech
Ag. (Acquired By Eurofins Scientific), Illumina,
Laboratory Corporation Of America, Merck
Kgaa, Natera Inc, Nipd Genetics, Premaitha Health Plc, Qiagen N.V, and Thermo Fisher Scientific
Inc.

Comments
Post a Comment